Press Enter to search · Esc to close
Remote and wearable monitoring is crossing from consumer gadget to clinically validated tool—with fresh evidence in heart failure, chronic kidney disease, and respiratory tracking.
A new wave of 2025 research suggests GLP-1 and dual GIP/GLP-1 drugs do more than shrink waistlines and tame A1c — they may protect the heart at the cellular level, and hint at effects we are only beginning to map.
A new wave of reviews argues that aging biology — not individual diseases — is medicine's highest-leverage target. Heart failure may be the proving ground.